This is an open label, randomized, multiple dose study to quantify the amount of Nonoxynol-9 (N-9) retained in the vagina at selected timepoints after instillation. Five different formulations will be studied (foam, 2 types of gel, cellophane, and suppository). For each formulation studied, at least 4 timepoints of retention (2 hr, 4 hr, 8 hr, and 12 hrs) will be studied. For the Advantage gel formulation, a 24 hour timepoint will also be studied. Each subject will be randomly assigned to receive the total series of instillations for one of the product formulations. For each product, a subject will be expected to complete 4 (or 5) instillations, one instillation for each assigned timepoint. At each study visit (separated by at least 5 days) , ONE of the selected timepoints will be studied. Each woman will undergo a vaginal lavage at the randomly assigned timepoint during the study visit. For each subject, the order that the time points are studied will be randomly assigned. Recent estimates suggest that over 75% of the 10-12 million HIV-infected adults worldwide have contracted the virus through heterosexual intercourse (1) . As of June 1992, heterosexual transmission became the primary mode of transmission of HIV to women in the United States (2). Currently, changes in sexual behavior and use of barrier contraception are the only ways to reduce the rate of heterosexual and homosexual (male to male) spread of these infections. In fact, male condoms, when used consistently and regularly, have been proven effective to prevent pregnancy (3), Human Immunodeficiency Virus (HIV) (4-6) and other sexually transmitted diseases (STDS) (7) and are recommended by the Public Health Service for use to prevent heterosexual transmission of HIV (8). However, it is important that every individual have a method he or she can use as personal protection against STDS, including HIV (9). To date 90% of clinical visits are completed and 80% of sample analysis has occurred. We anticipate completion/analysis May of 1997.

Project Start
Project End
Budget Start
1995-10-01
Budget End
1996-09-30
Support Year
24
Fiscal Year
1996
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Tipton, Laura; Cuenco, Karen T; Huang, Laurence et al. (2018) Measuring associations between the microbiota and repeated measures of continuous clinical variables using a lasso-penalized generalized linear mixed model. BioData Min 11:12
Juraschek, Stephen P; Woodward, Mark; Sacks, Frank M et al. (2017) Time Course of Change in Blood Pressure From Sodium Reduction and the DASH Diet. Hypertension 70:923-929
Anderegg, Nanina; Johnson, Leigh F; Zaniewski, Elizabeth et al. (2017) All-cause mortality in HIV-positive adults starting combination antiretroviral therapy: correcting for loss to follow-up. AIDS 31 Suppl 1:S31-S40
Tang, Olive; Miller 3rd, Edgar R; Gelber, Allan C et al. (2017) DASH diet and change in serum uric acid over time. Clin Rheumatol 36:1413-1417
Juraschek, Stephen P; Miller 3rd, Edgar R; Weaver, Connie M et al. (2017) Effects of Sodium Reduction and the DASH Diet in Relation to Baseline Blood Pressure. J Am Coll Cardiol 70:2841-2848
Segal, Leopoldo N; Clemente, Jose C; Tsay, Jun-Chieh J et al. (2016) Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nat Microbiol 1:16031
Aziz, Najib; Detels, Roger; Quint, Joshua J et al. (2016) Stability of cytokines, chemokines and soluble activation markers in unprocessed blood stored under different conditions. Cytokine 84:17-24
Cribbs, Sushma K; Uppal, Karan; Li, Shuzhao et al. (2016) Correlation of the lung microbiota with metabolic profiles in bronchoalveolar lavage fluid in HIV infection. Microbiome 4:3
Juraschek, Stephen P; Gelber, Allan C; Choi, Hyon K et al. (2016) Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet and Sodium Intake on Serum Uric Acid. Arthritis Rheumatol 68:3002-3009
Aziz, Najib; Detels, Roger; Chang, L Cindy et al. (2016) Macrophage Inflammatory Protein-3 Alpha (MIP-3?)/CCL20 in HIV-1-Infected Individuals. J AIDS Clin Res 7:

Showing the most recent 10 out of 749 publications